abstract |
The invention is directed to new inhibitors of the enzyme BACE1. Certain aspects of the invention are directed to compounds of formula (I), to pharmaceutical compositions containing these compounds, and the use of these compounds for the treatment of disorders to which the reduction of Aβ clusters has a beneficial effect, for example, Alzheimer's disease. |